INCIDENCE OF SEVERE OVARIAN HYPERSTIMULATION SYNDROME AFTER GNRH AGONIST/HMG SUPEROVULATION FOR INVITRO FERTILIZATION

被引：89

作者：

SMITZ, J

CAMUS, M

DEVROEY, P

ERARD, P

WISANTO, A

VANSTEIRTEGHEM, AC

机构：

[1] Centre for Reproductive Medicine, Academic Hospital, Vrije Universiteit Brussel, B 1090 Brussels

来源：

HUMAN REPRODUCTION | 1990年 / 5卷 / 08期

关键词：

GNRH AGONIST; INVITRO FERTILIZATION; OVARIAN STIMULATION; POLYCYSTIC OVARY DISEASE;

D O I：

10.1093/oxfordjournals.humrep.a137223

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In 1673 treatment cycles stimulated with buserelin and HMG, for IVF, GIFT or ZIFT, the severe ovarian hyperstimulation syndrome (OHSS) occurred in 10 cycles (0.6%). Eight patients were hyperandrogenic and showed an increased ovarian response to HMG. After replacement of a maximum of three embryos or zygotes, seven women became pregnant. Three women had a multiple gestation. All patients recovered uneventfully with conservative treatment. Support with progesterone or continuation of the agonist during the luteal phase did not prevent OHSS, confirming that the ovulatory HCG dose is the most important factor in inducing this severe complication. Luteal supplementation with HCG and/or HCG production during implantation could exacerbate OHSS.

引用

页码：933 / 937

页数：5

共 24 条

[1]

Belaisch-Allart J., De Mouzon J., The effect of luteal phase supplementation with HCG after ovulation stimulation using a LHRH/HMG analogue in in vitro fertilization programmes. Contr. Fertil, Sexual, 17, pp. 747-748, (1989)

[2]

Blankstein J., Bloom S., Lunenfeld B., Buvat J., Bringer J., Induction Et Stimulation De L’Ovulation, (1986)

[3]

Buvat J., Marcolin G., Guittard C., Herbaut J.C., Louvet, Dehaene A.L.J.L., Verbecq P., Renouard O., Luteal phase support after use of a LHRH agonist for in vitro fertilization: Superiority of HCG over oral progesterone. Contr. Fenil, Sexual, 17, pp. 745-747, (1989)

[4]

[5]

Charbonnel B., Krempfi M., Blanchard P., Dano F., Delage C., Induction of ovulation in polycystic ovary syndrome with a combination of a luteinising hormone-releasing hormone analog and exogenous gonadotrophins. Fertil, Steril, 47, pp. 920-924

[6]

Dor J., Itzkowic J., Maschiach S., Lunenfeld B., Serr D.M., Cumulative Conception Rates Following Gonadotrophin Therapy. Am. J. Obstet. Gynecol, 13, pp. 102-106, (1980)

[7]

Fleming R., Haxton M.J., Hamilton M., McCune R.P.G.S., Black W.P., Macnaughton M.C., Courts J.R.T., Successful treatment of infertile women with oligomenorrhea using a combination of an LHRH agonist and exogenous gonadotrophins, Br. J. Obstet. Gynaecol, 92, pp. 369-373, (1985)

[8]

Fleming R., Black W.P., Courts J.R.T., Effects of LH suppression in polycystic ovary syndrome. Clin, Endocrinol, 23, pp. 683-688, (1985)

[9]

Forman R.G., Frydman R., Egan D., Ross C., Barlow D., Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: A European series and a proposal for prevention. Fenil, Steril, 53, pp. 502-509, (1990)

[10]

Golan A., Ron-El R., Herman A., Weinraub Z., Soffer Y., Caspi E., Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropins for in vitro fertilization. Fenil, Steril, 50, pp. 912-916

← 1 2 3 →